Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 44Recurrence 9Sarcoma, Kaposi 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Plasmacytoma 1Plasmablastic Lymphoma 1Multi-centric Castleman's Disease 1Malignant Plasma Cell Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Epstein-Barr Virus Infections 1

Interventions

Lenalidomide 6Dexamethasone 6Cyclophosphamide 5Bortezomib 5fludarabine 3carfilzomib 3belantamab mafodotin 3pomalidomide 2fludarabine phosphate 2Melphalan 2Etoposide 2pembrolizumab 1isatuximab 1elotuzumab 1daratumumab 1Whole-Body Irradiation 1Thalidomide 1Tacrolimus 1Sirolimus 1Resistance Training 1Radiotherapy 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Methotrexate 1Exercise 1Equipment and Supplies 1Doxorubicin 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × pomalidomide × 90 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Takeda

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡